Amoeba SA (FR:ALMIB) has released an update.
Amoéba SA, a French greentech firm specializing in natural microbiological solutions, has announced the submission of a market authorization application for its AXPERA biofungicide product line to the US EPA, with an expected decision by mid-2025. The company has completed over 38 field trials in the US and more than 300 elsewhere to support the application. Amoéba is also collaborating with consultancy firm Dunham Trimmer to prepare for the commercial launch of AXPERA in the US, aiming for the first distribution contracts by the end of 2025.
For further insights into FR:ALMIB stock, check out TipRanks’ Stock Analysis page.
